Trastuzumab-mediated HER2 downregulation was shown in high HER2-expressing cancer cells in some of the earlier reports [12,13], but several studies with HER2-overexpressing cancer cells showed no HER2 downregulation by trastuzumab treatment [14-16]. This evidence concerns the gene ERBB2 and cancer.